CagriSema registration compares two dose levels with semaglutide over 72 weeks in obesity

This is a registration for a planned clinical study in humans, described as testing "how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight." The excerpt provided does not state the number of participants, so no sample size is reported here.

According to the registration, participants will receive either CagriSema or semaglutide, and the assignment is decided by chance. Three arms are listed: CagriSema at dose level 1, CagriSema at dose level 2, and semaglutide. The registration states that the overall study will last for about 83 weeks, with a 72-week treatment period in each arm.

No results appear in this material. The registration describes intent only: the stated purpose is to find out how safe and effective CagriSema is for body weight loss in these participants. Because this is a registration rather than a results publication, there are no outcome numbers, no adverse-event rates, and no comparison data to report.

The registration also notes a difference in regulatory position between the two treatments, stating that CagriSema is a new study medicine being tested while semaglutide is a medicine that doctors can already prescribe.

The registration describes route, frequency, and duration but not milligram amounts. Participants in the first experimental arm are to receive CagriSema at dose level 1 once weekly subcutaneously during the treatment period for 72 weeks, and participants in the second arm are to receive CagriSema at dose level 2 on the same schedule. Participants in the comparator arm are to receive semaglutide once weekly subcutaneously for 72 weeks.

The interventions section states that Cagrisema, described as cagrilintide and semaglutide, will be administered subcutaneously, and that semaglutide will be administered subcutaneously. The specific dose levels are not numerically defined in this excerpt.

This is a registration-only record: no participants' results are available, and nothing here demonstrates benefit or harm. The dose levels are labelled only as level 1 and level 2, so the actual amounts cannot be reported from this material. The excerpt does not state enrollment, study phase, recruitment status, trial sites, sponsor, funding, blinding, or the primary endpoint and its definition.

Two of the three listed arms are labelled active comparator, including one CagriSema arm, and no placebo arm is described in this excerpt. Registered plans can change, and planned studies may be amended, extended, or stopped without results being published.

Per this site's compound context, cagrilintide, also studied in coformulation as CagriSema, is not an FDA-approved drug for any use. That status comes from the site's regulatory review and not from this registration.